论文部分内容阅读
西妥昔单抗(cetuximab,商品名为爱必妥)为嵌合单克隆抗体,属于表皮生长因子受体抑制剂,静注用于转移性结肠直肠癌及头颈部癌症的治疗。该药由ImCloneSystems开发,在北美地区,由ImClone及施贵宝公司合作推广,在全球其它地区销售权归德国MerckKgaA所有。FDA在2004年批准了该药用于结肠直肠癌的治疗。
Cetuximab (Erbitux) is a chimeric monoclonal antibody that belongs to the epidermal growth factor receptor inhibitor. It is used intravenously for the treatment of metastatic colorectal cancer and head and neck cancer. Developed by ImClone Systems, the drug is marketed by ImClone and Squibb in North America and is sold by MerckKgaA in other parts of the world. FDA approved the drug in 2004 for the treatment of colorectal cancer.